Axonics, Inc. (AXNX)
- Previous Close
69.10 - Open
69.19 - Bid 49.75 x 200
- Ask 88.69 x 200
- Day's Range
68.70 - 69.19 - 52 Week Range
48.30 - 69.68 - Volume
558,927 - Avg. Volume
336,273 - Market Cap (intraday)
3.519B - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.02 - Earnings Date Oct 28, 2024 - Nov 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
www.axonics.comRecent News: AXNX
View MoreResearch Reports: AXNX
View MorePerformance Overview: AXNX
Trailing total returns as of 9/5/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AXNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AXNX
View MoreValuation Measures
Market Cap
3.52B
Enterprise Value
3.21B
Trailing P/E
--
Forward P/E
161.29
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.45
Price/Book (mrq)
5.47
Enterprise Value/Revenue
7.85
Enterprise Value/EBITDA
333.70
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.42%
Return on Assets (ttm)
-0.46%
Return on Equity (ttm)
-0.27%
Revenue (ttm)
408.81M
Net Income Avi to Common (ttm)
-1.71M
Diluted EPS (ttm)
-0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
343.41M
Total Debt/Equity (mrq)
5.05%
Levered Free Cash Flow (ttm)
24.39M